Widespread use of highly effective ART has increased the life expectancy of people living with HIV (PLWH) to close to that of the general population. But despite highly effective viral suppression, the risks for cardiovascular diseases continue to increase in these individuals. So too do the risks of neurocognitive impairment.
What do clinicians need to know to reduce these risks? What does the current evidence say, and how can those new findings best be applied?
Join us in this issue of eHIV Review, as guest author Jose Lucar MD, from the The George Washington University’s School of Medicine and Health Sciences, describes the evidence pointing to improved interventions to better maintain the health of these aging patients.
Assess factors associated with the aging population of PLWH that may complicate treatment or warrant special considerations.
Associate Professor, Division of Infectious Diseases, School of Medicine and Health Sciences
The George Washington University
Washington, DC
Nurse Educator
Boston Medical Center
Boston, MA
(he/him/his)
Assistant Professor
HIV, ID, and Global Medicine
Zuckerberg San Francisco General Hospital
San Francisco, California
(he/him/his)
Assistant Professor of Medicine and Pharmacology and Molecular Sciences
Division of Infectious Diseases
Division of Clinical Pharmacology
Johns Hopkins School of Medicine
Baltimore, Maryland
(she/her/hers)
0.5 hour Physicians
0.5 contact hour Nurses
Launch date: August 23, 2024
Expiration date: August 22, 2026